subscribeSubscribe
Santhera Concludes Agreement with French Authorities on Raxone Reimbursement

Santhera Concludes Agreement with French Authorities on Raxone Reimbursement
GLOBENEWSWIRE
08 Feb 2023
Share Share
Santhera Announces Positive Phase 4 LEROS Trial Data with Raxone

Santhera Announces Positive Phase 4 LEROS Trial Data with Raxone
GLOBENEWSWIRE
23 Jun 2021
Share Share
Chiesi`s Raxone recommended for use within NHS Wales

Chiesi`s Raxone recommended for use within NHS Wales
Lucy Parsons PHARMATIMES
26 Apr 2021
Share Share
Idebenone (Raxone®) is recommended for use within NHS Wales for the treatment

Idebenone (Raxone®) is recommended for use within NHS Wales for the treatment
NHS
22 Apr 2021
Share Share
Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa®

Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa®
GLOBENEWSWIRE
20 May 2020
Share Share
EMA validates Santhera’s Puldysa MAA

EMA validates Santhera’s Puldysa MAA
Anna Smith PHARMATIMES
27 Jun 2019
Share Share
Santhera submits MAA to EMA for Puldysa

Santhera submits MAA to EMA for Puldysa
Anna Smith PHARMA TIMES
28 May 2019
Share Share
Chiesi pays $105m to license ophthalmological drug

Chiesi pays $105m to license ophthalmological drug
Ben Hargreaves IN-PHA RMATECHNOLOGIST
28 May 2019
Share Share
Santhera, Chiesi Group Enter Raxone License Agreement

Santhera, Chiesi Group Enter Raxone License Agreement
CONTRACT PHARMA
24 May 2019
Share Share
Early access to Santhera’s DMD therapy Raxone extended in the UK

Early access to Santhera’s DMD therapy Raxone extended in the UK
Selina McKee PHARMA TIMES
23 Jun 2018
Share Share